Efficacy assessment in phase I clinical trials: endpoints and challenges

Area of Science:

• Oncology
• Clinical Pharmacology
• Drug Development

Background:

• Phase I oncology trials traditionally focus on safety but increasingly include therapeutic intent.
• Efficacy signals in Phase I trials significantly influence decisions for advancing new oncology drugs to Phase II.
• Assessing efficacy in small, heterogeneous Phase I populations requires flexible endpoint evaluation.

Purpose of the Study:

• To review the utility and limitations of classic efficacy endpoints in Phase I oncology trials.
• To explore the potential of novel efficacy endpoints for assessing antitumor activity in early-phase studies.
• To provide guidance on integrating diverse endpoints for improved early drug development decision-making.

Main Methods:

• Review of classic efficacy endpoints (e.g., objective response rate, progression-free survival, overall survival) in Phase I oncology trials.
• Discussion of challenges in efficacy assessment within small, heterogeneous patient cohorts.
• Exploration of emerging and novel endpoints for evaluating antitumor activity.

Main Results:

• Classic endpoints have limitations in Phase I oncology trials due to small sample sizes and study designs.
• Novel endpoints offer valuable insights into antitumor activity, complementing traditional measures.
• Integrated endpoint assessment enhances the evaluation of therapeutic efficacy in early drug development.

Conclusions:

• Phase I oncology trials require a nuanced approach to efficacy assessment beyond safety.
• Incorporating novel endpoints can overcome challenges in evaluating early antitumor responses.
• Optimized endpoint strategies in Phase I trials are crucial for effective novel oncology drug development.